Claims
- 1. An isolated nucleic acid molecule selected from the group consisting of:
a) a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, or a full complement thereof; and b) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2.
- 2. The nucleic acid molecule of claim 1, further comprising a vector nucleic acid sequence.
- 3. The nucleic acid molecule of claim 1, further comprising a nucleic acid sequence encoding a heterologous polypeptide.
- 4. A host cell which contains the nucleic acid molecule of claim 1.
- 5. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2.
- 6. The polypeptide of claim 5, further comprising heterologous amino acid sequences.
- 7. An antibody or antigen-binding fragment thereof that selectively binds to the polypeptide of claim 5.
- 8. A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:2, the method comprising culturing the host cell of claim 4 under conditions in which the nucleic acid molecule is expressed.
- 9. A method for detecting the presence of the polypeptide of claim 5 in a sample, the method comprising:
a) contacting the sample with an antibody that selectively binds to the polypeptide; and b) determining whether the compound binds to the polypeptide in the sample.
- 10. A kit comprising a compound that selectively binds to the polypeptide of claim 5 and instructions for use.
- 11. A method for detecting the presence of the nucleic acid molecule of claim 1 in a sample, the method comprising:
a) contacting the sample with a nucleic acid probe or primer that selectively hybridizes to the nucleic acid molecule; and b) determining whether the nucleic acid probe or primer binds to a nucleic acid in the sample.
- 12. The method of claim 11, wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.
- 13. A kit comprising a nucleic acid probe or primer that selectively hybridizes to the nucleic acid molecule of claim 1 and instructions for use.
- 14. A method for identifying a compound that binds to the polypeptide of claim 5, the method comprising:
a) contacting the polypeptide or a cell expressing the polypeptide with a test compound; and b) determining whether the polypeptide binds to the test compound.
- 15. A method for modulating the activity of the polypeptide of claim 5, the method comprising contacting the polypeptide or a cell expressing the polypeptide with a compound that binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.
- 16. A method of inhibiting aberrant activity of a 39362-expressing cell, comprising contacting the cell with a compound that modulates the activity or expression of the polypeptide of claim 5, in an amount that is effective to reduce or inhibit the aberrant activity of the cell.
- 17. The method of claim 16, wherein the compound is selected from the group consisting of a peptide, a phosphopeptide, a small organic molecule, and an antibody.
- 18. The method of claim 16, wherein the 39362-expressing cell is a cardiovascular cell.
- 19. A method of treating or preventing a disorder characterized by aberrant activity of a 39362-expressing cell, in a subject, the method comprising administering to the subject an effective amount of a compound that modulates the activity or expression of the nucleic acid molecule of claim 1, such that the aberrant activity of the 39362-expressing cell is reduced or inhibited.
- 20. The method of claim 19, wherein the 39362-expressing cell is a cardiovascular cell.
RELATED APPLICATIONS
[0001] This application claims priority to U.S. provisional application No. 60/260,286 filed on Jan. 8, 2001, the contents of which are incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60260286 |
Jan 2001 |
US |